Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T M Wheeler

Showing results (101-110 of 136) with videos related to

Pageof 14
Sort By:
Human Pathology|August 26, 1998
Clinical and pathological significance of the level and extent of capsular invasion in clinical stage T1-2 prostate cancerT M Wheeler, O Dillioglugil, M W Kattan, et al.
Cancer|January 15, 1998
Assessment of the biologic markers p53, Ki-67, and apoptotic index as predictive indicators of prostate carcinoma recurrence after surgeryA M Stapleton, P Zbell, M W Kattan, et al.
Human Pathology|August 3, 2000
Cytopathic effect of in situ gene therapy in prostate cancerG Ayala, T M Wheeler, M Shalev, et al.
Urology|August 30, 2000
Correlation of preoperative plasma IGF-I levels with pathologic parameters and progression in patients undergoing radical prostatectomyS F Shariat, F Bergamaschi, H L Adler, et al.
Cancer|January 15, 1995
The frequency of apoptosis correlates with the prognosis of Gleason Grade 3 adenocarcinoma of the prostateM Aihara, P T Scardino, L D Truong, et al.
The American Journal of Surgical Pathology|August 1, 1995
Interobserver reproducibility in the diagnosis of prostatic intraepithelial neoplasiaJ I Epstein, D J Grignon, P A Humphrey, et al.
Urology|February 13, 2001
E-cadherin expression predicts clinical outcome in carcinoma in situ of the urinary bladderS F Shariat, S Pahlavan, A G Baseman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 2, 2001
Preoperative plasma levels of transforming growth factor beta(1) (TGF-beta(1)) strongly predict progression in patients undergoing radical prostatectomyS F Shariat, M Shalev, A Menesses-Diaz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 1, 1996
Clustered p53 immunostaining: a novel pattern associated with prostate cancer progressionG Yang, A M Stapleton, T M Wheeler, et al.
Cancer|December 18, 2001
Predictive value of expression of transforming growth factor-beta(1) and its receptors in transitional cell carcinoma of the urinary bladderJ H Kim, S F Shariat, I Y Kim, et al.
Pageof 14

Showing results (101-110 of 136) with videos related to

Sort By:
Pageof 14
Human Pathology|August 26, 1998
Clinical and pathological significance of the level and extent of capsular invasion in clinical stage T1-2 prostate cancerT M Wheeler, O Dillioglugil, M W Kattan, et al.
Cancer|January 15, 1998
Assessment of the biologic markers p53, Ki-67, and apoptotic index as predictive indicators of prostate carcinoma recurrence after surgeryA M Stapleton, P Zbell, M W Kattan, et al.
Human Pathology|August 3, 2000
Cytopathic effect of in situ gene therapy in prostate cancerG Ayala, T M Wheeler, M Shalev, et al.
Urology|August 30, 2000
Correlation of preoperative plasma IGF-I levels with pathologic parameters and progression in patients undergoing radical prostatectomyS F Shariat, F Bergamaschi, H L Adler, et al.
Cancer|January 15, 1995
The frequency of apoptosis correlates with the prognosis of Gleason Grade 3 adenocarcinoma of the prostateM Aihara, P T Scardino, L D Truong, et al.
The American Journal of Surgical Pathology|August 1, 1995
Interobserver reproducibility in the diagnosis of prostatic intraepithelial neoplasiaJ I Epstein, D J Grignon, P A Humphrey, et al.
Urology|February 13, 2001
E-cadherin expression predicts clinical outcome in carcinoma in situ of the urinary bladderS F Shariat, S Pahlavan, A G Baseman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 2, 2001
Preoperative plasma levels of transforming growth factor beta(1) (TGF-beta(1)) strongly predict progression in patients undergoing radical prostatectomyS F Shariat, M Shalev, A Menesses-Diaz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 1, 1996
Clustered p53 immunostaining: a novel pattern associated with prostate cancer progressionG Yang, A M Stapleton, T M Wheeler, et al.
Cancer|December 18, 2001
Predictive value of expression of transforming growth factor-beta(1) and its receptors in transitional cell carcinoma of the urinary bladderJ H Kim, S F Shariat, I Y Kim, et al.
Pageof 14